Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23002243 | 1.00 | CBLB (1.00) | CBLB | |
| SCHEMBL22695549 | 1.00 | CBLB (1.00) | CBLB | |
| SCHEMBL22695546 | 0.89 | CBLB (1.00) | CBLB | |
| SCHEMBL22695508 | 0.89 | CBLB (1.00) | CBLB | |
| SCHEMBL23002231 | 0.89 | CBLB (1.00) | CBLB | |
| SCHEMBL29867488 | 0.89 | CBLB (0.84) | CBLB | |
| SCHEMBL21200380 | 0.89 | CBLB (0.84) | CBLB | |
| SCHEMBL29866624 | 0.88 | CBLB (1.00) | CBLB | |
| SCHEMBL21200497 | 0.88 | CBLB (1.00) | CBLB | |
| SCHEMBL21200367 | 0.88 | CBLB (0.81) | CBLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409555-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-12-12 | — | — | US | disclosed |
| US-12049471-B2 | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof | NURIX THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11530229-B2 | Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof | NURIX THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530229-B2 | Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof | NURIX THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| CN-114206855-A | Cyanocyclobutyl compounds for Cbl-b inhibition and uses thereof | 紐力克斯治疗公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20210087529-A1 | CBL INHIBITORS AND COMPOSITIONS FOR USE IN ADOPTIVE CELL THERAPY | NURIX THERAPEUTICS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210085717-A1 | CBL INHIBITORS AND COMPOSITIONS FOR EXPANSION OF IMMUNE CELLS | NURIX THERAPEUTICS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210053986-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210053986-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2020236654-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049471-B2 | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof | CBLB, CBL, CBLC | CBLB 1/4885 |
| US-20210087529-A1 | CBL INHIBITORS AND COMPOSITIONS FOR USE IN ADOPTIVE CELL THERAPY | CBL, CBLB, CBLC | CBLB 2/4885 |
| US-20210053986-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | CBLB, CBL, CBLC | CBLB 1/4885 |
| US-20240409555-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | CBLB, CBL, CBLC | CBLB 1/4885 |
| US-11530229-B2 | Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof | CBLB, CBL, CBLC | CBLB 1/4885 |
| US-20210085717-A1 | CBL INHIBITORS AND COMPOSITIONS FOR EXPANSION OF IMMUNE CELLS | CBL, CBLB, CBLC | CBLB 2/4885 |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | CBLB, CBL, CBLC | CBLB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.